Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22625179 | 0.92 | THRB (0.35) | THRBACHEBACE1 | |
| SCHEMBL25848355 | 0.89 | THRB (0.35) | THRBTP53SMN1; SMN2 | |
| SCHEMBL25848305 | 0.89 | MAOB (0.42) | THRBTP53SMN1; SMN2ACHEBACE1 | |
| SCHEMBL25848699 | 0.89 | THRB (0.34) | THRBTP53SMN1; SMN2MAOAMAOB | |
| SCHEMBL21735064 | 0.85 | THRB (0.36) | THRBACHEHPGDTSHR | |
| SCHEMBL21735755 | 0.85 | THRB (0.36) | THRBACHEHPGDTSHR | |
| SCHEMBL21735733 | 0.84 | S1PR1 (0.37) | THRBACHE | |
| SCHEMBL21735730 | 0.83 | THRB (0.35) | THRBACHE | |
| SCHEMBL25848642 | 0.82 | THRB (0.36) | THRBTP53SMN1; SMN2MAOB | |
| SCHEMBL25848386 | 0.82 | THRB (0.34) | THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702396-B2 | Hydrophobic compounds for optically active devices | Johnson & Johnson Surgical Vision, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702396-B2 | Hydrophobic compounds for optically active devices | UACA, CRYZ, TRPA1 | THRB 3289/4885TP53 2457/4885SMN1; SMN2 4872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.